UPDATED Sept. 25 at 11:15 a.m. with Jefferies report on reporting change for adverse events involving OmniPod
Wall Street Beat
Robotic surgery: Stryker agrees to pony up $1.65 billion for Mako Surgical
Weight loss: FDA asks for more info on EnteroMedics’ Maestro implant
Abiomed rebounds after reassuring on Medicare rate speculation
Langer brainchild Bind Therapeutics launches $70.5M IPO
Serial entrepreneur and Massachusetts biotech super-star Dr. Robert Langer’s Bind Therapeutics last week launched an initial public offering aimed at raising $70.5 million from shares sold at $15 apiece.
The clinical-stage company, co-founded by Langer and Dr. Omid Farokhzad, is developing nanotech-based solutions for "programmable" therapeutics, starting a pair of cancer drugs.
Despite a long road ahead, Sunshine Heart is worth a serious look
Edwards Lifesciences faces shareholder class action over Sapien TAVI system
Nanosphere closes $30M offering
Nanosphere (NSDQ:NSPH) pulled down $30.2 million in a public offering of some 17.3 million shares, including a substantial over-allotment snapped up by the offering’s underwriters.
General Electric backs Sonitus Medical with $10M loan
General Electric (NYSE:GE) said its GE Capital arm lent $10 million to Sonitus Medical for its SoundBite tooth-based hearing aid.
San Mateo, Calif.-based Sonitus plans to use the funds to expand commercialization of the SoundBite device, which uses bone conduction to transmit sound via the teeth, according to a press release.
Nanosphere prices $26M offering | Wall Street Beat
Nanosphere (NSDQ:NSPH) said it priced a public offering of 15 million shares at $1.75 apiece, aiming to drum up a minimum of $26.3 million for its molecular diagnostics technology.
Medtronic CEO unloads 10k shares | MassDevice.com On Call
MASSDEVICE ON CALL —Medtronic (NYSE:MDT) CEO Omar Ishrak this week unloaded 10,000 shares of company stock at an average price of about $53.58 apiece, a sale worth more than $535,000, according to SEC documents.
The per-share price is toward the higher end of the company’s 52-week average range, which has gone from $40.28 to $55.98.